Deerfield Management Company, L.P. (Series C) Merus N.V. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Merus N.V. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,408,539 shares of MRUS stock, worth $143 Million. This represents 3.17% of its overall portfolio holdings.
Number of Shares
3,408,539
Previous 2,749,401
23.97%
Holding current value
$143 Million
Previous $163 Million
4.68%
% of portfolio
3.17%
Previous 3.41%
Shares
10 transactions
Others Institutions Holding MRUS
# of Institutions
200Shares Held
61.9MCall Options Held
243KPut Options Held
300K-
Rtw Investments, LP New York, NY4.17MShares$174 Million3.32% of portfolio
-
Commodore Capital LP New York, NY3.35MShares$140 Million14.22% of portfolio
-
Wellington Management Group LLP Boston, MA2.89MShares$121 Million0.03% of portfolio
-
Samlyn Capital, LLC New York, NY2.61MShares$109 Million2.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.45MShares$103 Million4.42% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $1.92B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...